181 related articles for article (PubMed ID: 30564118)
1. A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions.
Lin TE; HuangFu WC; Chao MW; Sung TY; Chang CD; Chen YY; Hsieh JH; Tu HJ; Huang HL; Pan SL; Hsu KC
Front Pharmacol; 2018; 9():1379. PubMed ID: 30564118
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
4. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
[TBL] [Abstract][Full Text] [Related]
5. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
6. JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma.
Oh HN; Oh KB; Lee MH; Seo JH; Kim E; Yoon G; Cho SS; Cho YS; Choi HW; Chae JI; Shim JH
Phytomedicine; 2019 Jan; 52():60-69. PubMed ID: 30599913
[TBL] [Abstract][Full Text] [Related]
7. Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
Kim MK; Shin H; Park KS; Kim H; Park J; Kim K; Nam J; Choo H; Chong Y
J Med Chem; 2015 Sep; 58(18):7596-602. PubMed ID: 26351728
[TBL] [Abstract][Full Text] [Related]
8. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors.
Yang SH; Khadka DB; Cho SH; Ju HK; Lee KY; Han HJ; Lee KT; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):968-77. PubMed ID: 21185195
[TBL] [Abstract][Full Text] [Related]
10. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Xiong H; Du W; Zhang YJ; Hong J; Su WY; Tang JT; Wang YC; Lu R; Fang JY
Mol Carcinog; 2012 Feb; 51(2):174-84. PubMed ID: 21520296
[TBL] [Abstract][Full Text] [Related]
11. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
13. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
14. Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.
Li JJ; Cheng P; Tu J; Zhai HL; Zhang XY
Mol Biosyst; 2016 Feb; 12(2):575-87. PubMed ID: 26687880
[TBL] [Abstract][Full Text] [Related]
15. Role of a Janus kinase 2-dependent signaling pathway in platelet activation.
Lu WJ; Lin KC; Huang SY; Thomas PA; Wu YH; Wu HC; Lin KH; Sheu JR
Thromb Res; 2014 Jun; 133(6):1088-96. PubMed ID: 24731555
[TBL] [Abstract][Full Text] [Related]
16. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
17. Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening.
Vrontaki E; Melagraki G; Afantitis A; Mavromoustakos T; Kollias G
Mini Rev Med Chem; 2017; 17(3):268-294. PubMed ID: 27659251
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
20. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
